Roth Capital Starts MediciNova at Buy With $6 Target on ALS Drug
Phase 2b/3 ALS data due Q4 2026; cash runway into late 2027.
Phase 2b/3 ALS data due Q4 2026; cash runway into late 2027.
Barclays now sees two-times upside vs. downside for ALVO into December FDA reviews of Simponi, Eylea and Prolia biosimilars.
FDA let Rocket keep its 12-patient Danon study and count the first 3 patients. Needham upgraded RCKT and removed a key regulatory overhang.
The catalyst: an out-of-court deal that keeps exclusive rights to onvansertib. Cash remains tight.
Berenberg upgraded Eli Lilly from Hold to Buy and lifted its target to $1,400, citing obesity-drug leadership and a likely 2026 guidance beat.
Citizens cut Cellectis to Market Perform after it scrapped allogeneic CAR-T programs and pivoted to in-vivo gene editing for high triglycerides and cholesterol. Catalysts now 2027–28.